PLIN2, VLDL Biogenesis and Lipid Homeostasis

描述（由申请人提供）：脂肪分化相关蛋白（ADFP）、VLDL生物发生和甘油三酯稳态非酒精性脂肪性肝病（NAFLD）通常是慢性肝病的前兆，也是心血管疾病的预测因子。NAFLD的标志是肝细胞中存在大量脂滴（ld）。脂肪分化相关蛋白（Adipose differentiation related protein， ADFP）是结合在这些ld表面的最丰富的细胞质蛋白。它在脂质浸润性肝细胞（NAFLD）中表达上调。我产生了ADFP缺陷小鼠，发现与WT小鼠相比，这些小鼠的肝甘油三酯（TG）减少了60%。TG减少在细胞质中是明显的，但是，矛盾的是，与野生型小鼠相比，ADFP缺陷小鼠微粒体部分的TG增加。同时，ADFP缺陷小鼠微粒体甘油三酯转移蛋白（MTP）在蛋白质水平上增加，但在mRNA水平上没有增加，并且VLDL分泌增加。肝脂质的摄取、产生和利用没有改变。在这个应用中，我将追求三个具体目标：(1)确定ADFP缺陷相关的肝脏MTP蛋白上调的分子机制，(2)确定MTP和ADFP在调节肝脏TG稳态中的相互作用。(3)研究心脏Adfp缺乏症。我将使用肝细胞系、心肌细胞、原代肝细胞、转化Adfp缺陷肝细胞、Adfp缺陷和MTP条件敲除小鼠作为模型。我还将生成条件Adfp靶向小鼠。我将结合使用药理学和分子工具，如MTP抑制剂、siRNA和重组辅助腺病毒，来抑制或增强这些模型细胞和动物中的基因表达。我想要达到的最终目标是：(1)确定ADFP缺乏时MTP蛋白上调的机制，(2)找到ADFP缺乏相关的肝脏TG降低和心脏TG升高的机制，(3)验证ADFP参与LD形成和调节可能代表一种与MTP竞争TG并负向调节VLDL分泌的细胞质蛋白，当其过度表达时导致肝脏脂肪变性的假设。（iv）确定影响Adfp缺乏时肝脏和心脏TG储存的因素。我的长期目标是了解ADFP和其他LD相关蛋白在LD形成和成熟中的功能，以及这如何影响肝脏和心脏TG动力学的调节，如脂蛋白组装和分泌，以及肝脏、心脏和其他器官的脂质稳态。

DESCRIPTION (provided by applicant): Adipose Differentiation Related Protein (ADFP), VLDL Biogenesis and Triacylglycerol Homeostasis Nonalcoholic fatty liver disease (NAFLD) is often a precursor to chronic liver diseases, and a predictor of cardiovascular disease. The hallmark of NAFLD is the presence of numerous lipid droplets (LDs) in the hepatocytes. Adipose differentiation related protein (ADFP) is the most abundant cytosolic protein that binds to the surface of these LDs. Its expression is upregulated in lipid infiltrated hepatocytes (in NAFLD). I generated ADFP deficient mice and found a 60% reduction in hepatic triacylglycerol (TG) in these mice compared to WT mice. The TG reduction is pronounced in the cytosol, but, paradoxically, TG is increased in the microsome fraction in ADFP deficient as compared with wildtype mice. Concomitantly, there is an increase in the amount of microsomal triglyceride transfer protein (MTP) at the protein level, but not mRNA level, and a increase in VLDL secretion in the ADFP deficient mice. The hepatic lipid uptake, production and utilization are not altered. In this application, I will pursue three specific aims: (1) to identify the molecular mechanism of ADFP deficiency-associated hepatic MTP protein upregulation, (2) to determine the interplay between MTP and ADFP in modulating hepatic TG homeostasis., and (3) to study Adfp deficiency in the heart. I will use hepatic cell lines, cardiomyocytes, primary hepatocytes, transformed Adfp deficient hepatic cells, ADFP deficient and MTP conditional knockout mice as models. I will also generate conditional Adfp targeting mice. I will apply a combination of pharmacological and molecular tools such as MTP inhibitor, siRNA and recombinant helper dependent adenovirus to suppress or augment gene expression in these model cells and animals. The ultimate objectives I want to achieve are (i) to determine the mechanism of MTP protein upregulation in ADFP deficiency, (ii) to find the mechanism of ADFP deficiency-associated hepatic TG reduction and cardiac TG elevation, (iii) to test the hypothesis that ADFP, with its involvement in LD formation and regulation may represent a cytosolic protein which compete with MTP for TG and negatively regulate VLDL secretion while causing hepatic steatosis when it is overexpressed, and (iv) to identify factors that affect liver and heart TG storage in Adfp deficiency. My long term goal is to understand the function of ADFP and other LD- associated proteins in the formation and maturation of LD and how this affects the regulation of hepatic and cardiac TG dynamics such as lipoprotein assembly and secretion, and lipid homeostasis in liver heart and other organs.